Durga Kanigicherla

Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy

Durga Kanigicherla, Jennet Gummadova, Edward A. McKenzie et al. · Kidney International · 2013 · 345 citations

Life Sciences, Immunology, Nephrology +11

Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy

Jonathan Barratt, Richard Lafayette, Jens Kristensen et al. · Kidney International · 2022 · 215 citations · Full text

Pharmacy, Nephrology, Pharmacotherapy +13

Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

Hiddo J.L. Heerspink, Jai Radhakrishnan, Charles E. Alpers et al. · The Lancet · 2023 · 215 citations · Full text

Medicine, Internal Medicine, Nephrology +12

Long-term outcomes of persistent disease and relapse in primary membranous nephropathy

Durga Kanigicherla, Colin D. Short, Stephen A. Roberts et al. · Nephrology Dialysis Transplantation · 2016 · 37 citations · Full text

Medicine, Nephrology, Pediatric Nephrology +13

Rituximab versus the modified Ponticelli regimen in the treatment of primary membranous nephropathy: a Health Economic Model

Patrick Hamilton, Durga Kanigicherla, Michael Venning et al. · Nephrology Dialysis Transplantation · 2018 · 25 citations · Full text

Pharmacy, Nephrology, Pharmacoeconomics +16